USNA Usana Health Sciences Inc
Price (delayed)
$31.78
Market cap
$605.71M
P/E Ratio
11.19
Dividend/share
N/A
EPS
$2.84
Enterprise value
$240.82M
USANA prides itself in providing consumers the highest quality nutritional products in the world. From its award-winning supplements to its innovative skincare line, USANA has proven for more than 25
Highlights
USNA's debt has plunged by 100% YoY
The price to earnings (P/E) is 27% lower than the 5-year quarterly average of 15.4 and 26% lower than the last 4 quarters average of 15.1
USNA's net income is down by 9% year-on-year
The EPS has contracted by 8% YoY
Key stats
What are the main financial stats of USNA
Market
Valuations
Earnings
Shares outstanding
19.06M
Market cap
$605.71M
Enterprise value
$240.82M
Price to earnings (P/E)
11.19
Price to book (P/B)
1.14
Price to sales (P/S)
0.7
EV/EBIT
2.59
EV/EBITDA
2.11
EV/Sales
0.28
Revenue
$861.97M
Gross profit
$697M
Operating income
$82.33M
Net income
$54.34M
EBIT
$92.83M
EBITDA
$114.05M
Free cash flow
$65.7M
Per share
Balance sheet
Liquidity
EPS
$2.84
EPS diluted
$2.83
Free cash flow per share
$3.44
Book value per share
$27.98
Revenue per share
$45.18
TBVPS
$32.75
Total assets
$671.31M
Total liabilities
$138.22M
Debt
$0
Equity
$533.09M
Working capital
$336.41M
Debt to equity
0
Current ratio
3.93
Quick ratio
3.18
Net debt/EBITDA
-3.2
Margins
Efficiency
Dividend
EBITDA margin
13.2%
Gross margin
80.9%
Net margin
6.3%
Operating margin
9.6%
Return on assets
8.5%
Return on equity
10.6%
Return on invested capital
64.5%
Return on capital employed
16.7%
Return on sales
10.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
USNA stock price
How has the Usana Health Sciences stock price performed over time
Intraday
-0.97%
1 week
0.28%
1 month
-7.56%
1 year
-35.54%
YTD
-11.45%
QTD
-11.45%
Financial performance
How have Usana Health Sciences's revenue and profit performed over time
Revenue
$861.97M
Gross profit
$697M
Operating income
$82.33M
Net income
$54.34M
Gross margin
80.9%
Net margin
6.3%
The operating income has declined by 10% year-on-year and by 2.4% since the previous quarter
USNA's net income is down by 9% year-on-year
The gross profit has declined by 7% year-on-year
USNA's revenue is down by 7% year-on-year
Growth
What is Usana Health Sciences's growth rate over time
Valuation
What is Usana Health Sciences stock price valuation
P/E
11.19
P/B
1.14
P/S
0.7
EV/EBIT
2.59
EV/EBITDA
2.11
EV/Sales
0.28
The price to earnings (P/E) is 27% lower than the 5-year quarterly average of 15.4 and 26% lower than the last 4 quarters average of 15.1
The EPS has contracted by 8% YoY
USNA's P/B is 64% below its 5-year quarterly average of 3.2 and 33% below its last 4 quarters average of 1.7
The company's equity rose by 7% YoY and by 4.1% QoQ
USNA's price to sales (P/S) is 46% less than its 5-year quarterly average of 1.3 and 30% less than its last 4 quarters average of 1.0
USNA's revenue is down by 7% year-on-year
Efficiency
How efficient is Usana Health Sciences business performance
The ROE has contracted by 15% YoY and by 3.6% from the previous quarter
The company's return on invested capital fell by 14% YoY and by 3.4% QoQ
Usana Health Sciences's ROA has decreased by 11% YoY and by 2.3% from the previous quarter
Dividends
What is USNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for USNA.
Financial health
How did Usana Health Sciences financials performed over time
Usana Health Sciences's total liabilities has increased by 16% QoQ
The quick ratio has grown by 14% YoY
USNA's debt is 100% less than its equity
USNA's debt has plunged by 100% YoY
The company's equity rose by 7% YoY and by 4.1% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.